Differential MMP-14 Targeting by Lumican-Derived Peptides Unraveled by In Silico Approach.

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• Lumican, a small leucine-rich proteoglycan (SLRP), inhibits tumor growth via MMP-14 interaction.
• Lumican-derived peptides like lumcorin and L9M show potential in inhibiting melanoma progression.

Purpose of the Study:

• To visualize and characterize interactions between lumican-derived peptides (lumcorin, L9M, L9Mc) and MMP-14 using molecular modeling.
• To validate in silico findings through in vitro and in vivo biological assays.

Main Methods:

• Molecular modeling to predict peptide-MMP-14 interactions.
• MMP-14 activity assays.
• Cell migration and proliferation assays using B16F1 and HT-144 melanoma cells.
• In vivo tumor growth assessment.

Main Results:

• Molecular modeling identified distinct interaction sites: L9Mc with MMP-14's MT-Loop, lumcorin with the catalytic site.
• L9Mc significantly inhibited B16F1 cell migration, proliferation, and tumor growth, but less effectively than lumcorin.
• Biological assays validated the in silico predictions regarding peptide-MMP-14 interactions and inhibitory effects.

Conclusions:

• The distinct interaction domains of lumican-derived peptides with MMP-14 explain their varied inhibitory efficacies.
• Computational and biological data confirm the anti-melanoma potential of lumican-derived peptides, particularly L9Mc.